Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Danaher Corp.
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Emmanuel Ligner, president and CEO of Cytiva, talks to In Vivo about how the company will dramatically increase its manufacturing capabilities over the next five years, at a price tag of $500m.
While the main role of SARS-CoV-2 antibody testing is currently limited to determining exposure to the virus in populations, the scientific community is working hard to define the neutralizing properties of the antibodies detected, and the duration of the immune response. As a result, antibody testing could be here to stay for the long term for monitoring populations, testing vaccines and selecting patients for trials of a variety of new therapies to treat numerous conditions.
- In Vitro Diagnostics
- Medical Devices
- Research, Analytical Equipment & Supplies
- Other Names / Subsidiaries
- Beckman Coulter
- GE Life Sciences
- Pall Corporation
- Radiometer Medical ApS
- HemoCue AB
- Integrated DNA Technologies, Inc.
- Leica Microsystems Inc.
- Leica Biosystems Inc.
- Vision Systems Ltd.
- Coretech Holdings, LLC
- Q3DM Inc.
- Aldevron LLC